Pharma stocks had a mixed response after Finance Minister Nirmala Sitharaman announced customs duty exemptions for 36 ...

Finance Minister Sitharaman announced the inclusion of six life-saving drugs in the concessional 5% duty slab to enhance ...

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials ...

Mumbai: In a fresh challenge to Novartis' blockbuster heart failure drug Entresto, Indian generics maker Lupin has received ...

Mumbai: Global pharma major Lupin Limited and Avas Pharmaceuticals SRL have announced the launch of Lupin's orphan drug ...

Lupin and Avas launch NaMuscla in Italy to treat myotonia in adults with NDM disorders: Our Bureau, Mumbai Tuesday, January 28, 2025, 16:45 Hrs [IST] Global pharma major Lupin Lim ...

Lupin and Avas Launch NaMuscla® in Italy Enables expanded access to the only EU-approved treatment for the myotonia symptoms in adults with non-dystrophic myotonic disorders Mumbai, Zug, January ...

Global pharma major Lupin Limited (Lupin) and Avas Pharmaceuticals SRL (Avas) today announced the launch of Lupin's orphan ...

Rising prevalence of diabetes, recent product approvals & product launches in the market are the major factors driving the market for incretin-based drugs.

This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who ...